mazindol + metformin

Mazindol + metformin is a fixed-dose combination of two small molecule drugs used primarily for the management of obesity, particularly in patients with prediabetes or additional risk factors for type 2 diabetes. Mazindol is a sympathomimetic amine anorectic agent that acts as an appetite suppressant by inhibiting the reuptake of norepinephrine and dopamine in the central nervous system, leading to reduced food intake. Metformin is a biguanide antihyperglycemic agent that improves insulin sensitivity and decreases hepatic glucose production. The combination has demonstrated additive effects on weight reduction and glycemic control compared to either drug alone, especially in prediabetic obese individuals. Additionally, studies suggest potential anxiolytic properties when used together. This combination may be useful for preventing or delaying progression to type 2 diabetes in high-risk obese populations[1][2][3][4].

Other names

mazindol-metforminmetformin-mazindol